Clinical study of Weierkang pills combined with triple therapy for Helicobacter pylori infectio

Phase 4

• Conditions: Heilicobacter pylori infection

• Registration Number: ITMCTR2000003109
• Lead Sponsor: Department of Gastroenterology, Run Run Shaw Hospital of Zhejiang University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Voluntarily sign the informed consent;
2. The age is more than 18 years old, men and women are not limited;
3. Patients who were Hp positive without anti-bacterial treatment;

Exclusion Criteria

1. Patients who have used antibiotics or bismuth agent within 4 weeks; Patients who had used antacids (H2 antagonists or proton pump inhibitors), prokinetic drugs (mosapride or doperidone, etc.) and gastric mucosa protectants (tipredone, sucralose, rabapet, etc.) in the previous 2 weeks;
2. Patients with serious lesions in important organs of the body (heart, liver, kidney, lung, etc.);
3. Patients diagnosed with gastric cancer by gastroscopy or other examinations;
4. Pregnant and nursing women;
5. Unable to follow visitors or allergic to this study.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hp eradication rate;Incidence of adverse reactions;

Secondary Outcome Measures

Name	Time	Method
Symptom remission rate;